First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Hong S, Wang Q, Cheng Y, Luo Y, et al. Nat Med 2025 Aug 19. doi: 10.1038/s41591-025-03883.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hong S, Wang Q, Cheng Y, Luo Y, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med 2025 Aug 19. doi: 10.1038/s41591-025-03883.
PMID: 40830660